Most Read Articles
Rachel Soon, 6 days ago

On 8 August, the first town hall held by the Ministry of Health (MOH) with members of the pharmacy profession took place in Putrajaya. Over 500 pharmacists from across the country and from different areas of practice—community and hospital, public and private, academy and industry—converged to fill the auditorium for the chance to engage in direct dialogue with MOH.

Jackey Suen, 08 Oct 2018

Adding pertuzumab to trastuzumab plus an aromatase inhibitor (AI) improves progression-free survival (PFS) in patients with HER2-positive metastatic or locally advanced breast cancer, the phase II PERTAIN study has shown.

05 Aug 2019
Use of alpha blockers in the treatment of hypertension in women is associated with an increased risk of hypotension and related events as compared with other blood pressure-lowering drugs, as reported in a recent study.
Dr. Bryan Li, Dr. Gerry Kwok, Dr. Thomas Yau, 07 Aug 2019

Case 1: A 59-year-old gentleman with advanced HCC was referred to our centre for management. He had a history of diabetes, hypertension and ischaemic heart disease. He was a nondrinker and not a carrier of hepatitis B or C.

Case 2: A 65-year-old man with a history of alcoholic cirrhosis and oesophageal varices was found to have rising AFP levels on routine follow-up. He also had a 3-year history of diabetes and was on diet control, with an HbA1c of 6.2 percent and fasting glucose of 6.8 mmol/L. He did not need any diabetic medications.

Biosimilar CT-P13 on par with infliximab in Crohn’s Disease

06 Feb 2019

CT-P13 is as effective as its reference product (RP) infliximab for infliximab-naïve patients with Crohn’s disease (CD), suggests a recent study. Safety outcomes are also comparable between the two drugs.

The composite endpoint of death, CD-related surgery, all-cause hospitalization and reimbursement of another biologic therapy present in a total of 1,147 patients in the RP group and 952 in the CT-P13 group, as well as 838 and 719 hospitalizations, respectively.

Multivariable analysis revealed that CT-P13 was on a par with RP (HR, 0.92; 95 percent CI, 0.85–0.99). There were no between-group differences observed in safety outcomes: serious infections (HR, 0.82; 0.61–1.11), tuberculosis (HR, 1.10; 0.36–3.34), and solid or haematologic cancer (HR, 0.66; 0.33–1.32).

This comparative equivalence cohort study included 5,050 infliximab-naïve CD patients aged >15 years, who had started treatment with RP (n=2,551) or CT-P13 (n=2,400) and had no other indications for infliximab. Equivalence was defined as a 95 percent CI of the HR of CT-P14 vs RP in a multivariable marginal Cox model situated within prespecified margins (0.80–1.25).

The study was limited by incomplete clinical data from the Système National des Données de Santé, a French nationwide health administrative database (1 March 2015 to 30 June 2017).

“CT-P13 is a biosimilar of the RP infliximab, with demonstrated efficacy and safety for some inflammatory arthritides. It was approved for the treatment of CD on that basis, without specific studies examining its effects in CD,” the investigators noted.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Rachel Soon, 6 days ago

On 8 August, the first town hall held by the Ministry of Health (MOH) with members of the pharmacy profession took place in Putrajaya. Over 500 pharmacists from across the country and from different areas of practice—community and hospital, public and private, academy and industry—converged to fill the auditorium for the chance to engage in direct dialogue with MOH.

Jackey Suen, 08 Oct 2018

Adding pertuzumab to trastuzumab plus an aromatase inhibitor (AI) improves progression-free survival (PFS) in patients with HER2-positive metastatic or locally advanced breast cancer, the phase II PERTAIN study has shown.

05 Aug 2019
Use of alpha blockers in the treatment of hypertension in women is associated with an increased risk of hypotension and related events as compared with other blood pressure-lowering drugs, as reported in a recent study.
Dr. Bryan Li, Dr. Gerry Kwok, Dr. Thomas Yau, 07 Aug 2019

Case 1: A 59-year-old gentleman with advanced HCC was referred to our centre for management. He had a history of diabetes, hypertension and ischaemic heart disease. He was a nondrinker and not a carrier of hepatitis B or C.

Case 2: A 65-year-old man with a history of alcoholic cirrhosis and oesophageal varices was found to have rising AFP levels on routine follow-up. He also had a 3-year history of diabetes and was on diet control, with an HbA1c of 6.2 percent and fasting glucose of 6.8 mmol/L. He did not need any diabetic medications.